EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of whole lung irradiation in lung metastatic rhabdomyosarcoma: A pooled analysis of two European trials and one European registry

Amadeus T Heinz iD, Philip Heesen, Johannes H M Merks, Véronique Minard-Colin iD, Martin Ebinger, Alison L Cameron, Semi Harrabi iD, Henry Mandeville, Reineke A Schoot, Jörg Fuchs, Gabriela Guillen, Ewa Koscielniak iD und 3 weitere

Cancer · 01.08.2026 · 132 (15)

DOI: 10.1002/cncr.70530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 23.07.2026. Verfasst von Amadeus T Heinz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: Lung Neoplasms, Rhabdomyosarcoma. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Città della Speranza, Royal Marsden Cancer Charity, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung metastases in patients with metastatic rhabdomyosarcoma (RMS) have not been treated uniformly across Europe. This provides comparison of the impact of whole lung irradiation (WLI).

Methods

Lung‐metastatic patients included in the Cooperative Weichteilsarkom Studiengruppe‐IV 2002, European Pediatric Soft Tissue Sarcoma Study Group MTS 2008 or the Soft Tissue Sarcoma Registry received four‐ or six‐drug chemotherapy, surgery, and/or irradiation (radiotherapy) of the primary tumor. Treatment of lung lesions consisted of metastasectomy, WLI, or no local treatment according to protocols.

Results

A total of 238 patients with lung‐metastatic RMS were included. Half of these patients ( n = 119/238) had lung metastases only (median age, 6.6 years), mainly classified as embryonal RMS ( n = 93/119, 78%). Lung‐only patients underwent metastasectomy ( n = 17) and/or WLI ( n = 31) or no local treatment of lung metastases ( n = 71). Early complete response of lung metastases was associated with favorable 3‐year overall survival ( p = .009). A trend toward improved event‐free survival after WLI could be identified in patients ≥10 years old (hazard ratio [HR], 2.7; 95% CI, 0.8–9.6), but not in patients under 10 years old (HR, 0.86; 95% CI, 0.44–1.66). Lung–relapse‐free survival (lung‐RFS) was not influenced by WLI or metastasectomy in the univariable and multivariable analyses. When analyzing all lung‐metastatic patients (including those with metastases in other sites, n = 238), WLI in patients older than 10 years was a significant prognostic factor (HR, 2.2; 95% CI, 1.0–4.9).

Conclusions

The analysis failed to show a significant benefit of WLI in patients with lung‐metastatic RMS, apart from the subgroup of patients older than 10 years. Lung‐RFS was not influenced by WLI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsRhabdomyosarcomaHumansChildFemaleMaleRegistriesChild, PreschoolAdolescentEuropeInfantMetastasectomyCombined Modality TherapyTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

CWSEpSSGWLIlung irradiationlung metastasesresponserhabdomyosarcomasingle site metastases

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany.
  • Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital), Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany.
  • University Hospital USZ, University of Zurich, Zurich, Switzerland.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Division of Imaging and Oncology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands.
  • Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

ORCID-Profile: Amadeus T Heinz, Véronique Minard-Colin, Semi Harrabi, Ewa Koscielniak, Julia C Chisholm, Monika Sparber-Sauer, Gianni Bisogno

Förderung

  • Fondazione Città della Speranza
  • Royal Marsden Cancer Charity
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • Deutsche Kinderkrebsstiftung
  • Förderkreis Krebskranke Kinder Stuttgart
  • Stiftung des Fördervereins für Krebskranke Kinder Tübingen

Zitieren

APA

Heinz, A. T., Heesen, P., Merks, J. H. M., Minard-Colin, V., Ebinger, M., Cameron, A. L., Harrabi, S., Mandeville, H., Schoot, R. A., Fuchs, J., Guillen, G., Koscielniak, E., Chisholm, J. C., Sparber-Sauer, M., & Bisogno, G. (2026). The impact of whole lung irradiation in lung metastatic rhabdomyosarcoma: A pooled analysis of two European trials and one European registry. Cancer, 132(15). https://doi.org/10.1002/cncr.70530

Vancouver

Heinz AT, Heesen P, Merks JHM, Minard-Colin V, Ebinger M, Cameron AL, et al. The impact of whole lung irradiation in lung metastatic rhabdomyosarcoma: A pooled analysis of two European trials and one European registry. Cancer. 2026;132(15). doi:10.1002/cncr.70530

BibTeX
@article{Heinz2026,
  author = {Heinz, Amadeus T and Heesen, Philip and Merks, Johannes H M and Minard-Colin, Véronique and Ebinger, Martin and Cameron, Alison L and Harrabi, Semi and Mandeville, Henry and Schoot, Reineke A and Fuchs, Jörg and Guillen, Gabriela and Koscielniak, Ewa and Chisholm, Julia C and Sparber-Sauer, Monika and Bisogno, Gianni},
  title = {The impact of whole lung irradiation in lung metastatic rhabdomyosarcoma: A pooled analysis of two European trials and one European registry},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {15},
  doi = {10.1002/cncr.70530}
}
Kostenlos starten →